Revelation Biosciences Stock Net Income
| REVB Stock | USD 0.52 0.03 5.45% |
As of the 28th of January, Revelation Biosciences holds the Coefficient Of Variation of (480.74), risk adjusted performance of (0.14), and Variance of 27.44. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Revelation Biosciences, as well as the relationship between them.
Revelation Biosciences Total Revenue |
|
| Last Reported | Projected for Next Year | ||
| Net Loss | -13.5 M | -12.9 M | |
| Net Loss | -1.9 M | -1.8 M | |
| Net Loss | -13.5 M | -12.9 M | |
| Net Loss | (78.91) | (82.86) |
Revelation | Net Income | Build AI portfolio with Revelation Stock |
Latest Revelation Biosciences' Net Income Growth Pattern
Below is the plot of the Net Income of Revelation Biosciences over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Revelation Biosciences financial statement analysis. It represents the amount of money remaining after all of Revelation Biosciences operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Revelation Biosciences' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Revelation Biosciences' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (15.04 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Revelation Net Income Regression Statistics
| Arithmetic Mean | 993,773 | |
| Geometric Mean | 3,367,415 | |
| Coefficient Of Variation | 1,143 | |
| Mean Deviation | 8,524,475 | |
| Median | 4,505,000 | |
| Standard Deviation | 11,357,409 | |
| Sample Variance | 129T | |
| Range | 42.7M | |
| R-Value | (0.61) | |
| Mean Square Error | 87.2T | |
| R-Squared | 0.37 | |
| Significance | 0.01 | |
| Slope | (1,361,703) | |
| Total Sum of Squares | 2063.9T |
Revelation Net Income History
Other Fundumenentals of Revelation Biosciences
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Revelation Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Revelation Biosciences is extremely important. It helps to project a fair market value of Revelation Stock properly, considering its historical fundamentals such as Net Income. Since Revelation Biosciences' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Revelation Biosciences' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Revelation Biosciences' interrelated accounts and indicators.
Click cells to compare fundamentals
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Revelation Biosciences. If investors know Revelation will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Revelation Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Revelation Biosciences is measured differently than its book value, which is the value of Revelation that is recorded on the company's balance sheet. Investors also form their own opinion of Revelation Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Revelation Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Revelation Biosciences' market value can be influenced by many factors that don't directly affect Revelation Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Revelation Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Revelation Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Revelation Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Revelation Biosciences 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Revelation Biosciences' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Revelation Biosciences.
| 10/30/2025 |
| 01/28/2026 |
If you would invest 0.00 in Revelation Biosciences on October 30, 2025 and sell it all today you would earn a total of 0.00 from holding Revelation Biosciences or generate 0.0% return on investment in Revelation Biosciences over 90 days. Revelation Biosciences is related to or competes with Scisparc, Onconetix, Indaptus Therapeutics, GT Biopharma, Avenue Therapeutics, Psyence Biomedical, and Azitra. Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercializati... More
Revelation Biosciences Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Revelation Biosciences' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Revelation Biosciences upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.22) | |||
| Maximum Drawdown | 34.24 | |||
| Value At Risk | (8.70) | |||
| Potential Upside | 5.56 |
Revelation Biosciences Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Revelation Biosciences' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Revelation Biosciences' standard deviation. In reality, there are many statistical measures that can use Revelation Biosciences historical prices to predict the future Revelation Biosciences' volatility.| Risk Adjusted Performance | (0.14) | |||
| Jensen Alpha | (1.26) | |||
| Total Risk Alpha | (1.59) | |||
| Treynor Ratio | (0.49) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Revelation Biosciences' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Revelation Biosciences January 28, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.14) | |||
| Market Risk Adjusted Performance | (0.48) | |||
| Mean Deviation | 3.53 | |||
| Coefficient Of Variation | (480.74) | |||
| Standard Deviation | 5.24 | |||
| Variance | 27.44 | |||
| Information Ratio | (0.22) | |||
| Jensen Alpha | (1.26) | |||
| Total Risk Alpha | (1.59) | |||
| Treynor Ratio | (0.49) | |||
| Maximum Drawdown | 34.24 | |||
| Value At Risk | (8.70) | |||
| Potential Upside | 5.56 | |||
| Skewness | (1.31) | |||
| Kurtosis | 4.88 |
Revelation Biosciences Backtested Returns
Revelation Biosciences maintains Sharpe Ratio (i.e., Efficiency) of -0.24, which implies the firm had a -0.24 % return per unit of risk over the last 3 months. Revelation Biosciences exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check Revelation Biosciences' Coefficient Of Variation of (480.74), risk adjusted performance of (0.14), and Variance of 27.44 to confirm the risk estimate we provide. The company holds a Beta of 2.27, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Revelation Biosciences will likely underperform. At this point, Revelation Biosciences has a negative expected return of -1.3%. Please make sure to check Revelation Biosciences' potential upside, daily balance of power, as well as the relationship between the Daily Balance Of Power and price action indicator , to decide if Revelation Biosciences performance from the past will be repeated at some point in the near future.
Auto-correlation | -0.06 |
Very weak reverse predictability
Revelation Biosciences has very weak reverse predictability. Overlapping area represents the amount of predictability between Revelation Biosciences time series from 30th of October 2025 to 14th of December 2025 and 14th of December 2025 to 28th of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Revelation Biosciences price movement. The serial correlation of -0.06 indicates that barely 6.0% of current Revelation Biosciences price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.06 | |
| Spearman Rank Test | -0.02 | |
| Residual Average | 0.0 | |
| Price Variance | 0.01 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Revelation Biosciences reported net income of (15.04 Million). This is 104.41% lower than that of the Biotechnology sector and 121.47% lower than that of the Health Care industry. The net income for all United States stocks is 102.63% higher than that of the company.
Revelation Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Revelation Biosciences' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Revelation Biosciences could also be used in its relative valuation, which is a method of valuing Revelation Biosciences by comparing valuation metrics of similar companies.Revelation Biosciences is currently under evaluation in net income category among its peers.
Revelation Biosciences Current Valuation Drivers
We derive many important indicators used in calculating different scores of Revelation Biosciences from analyzing Revelation Biosciences' financial statements. These drivers represent accounts that assess Revelation Biosciences' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Revelation Biosciences' important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 100.7M | 10.8M | 10.3M | 3.8M | 4.4M | 4.1M | |
| Enterprise Value | 99.4M | 5.5M | (1.7M) | (2.7M) | (3.1M) | (3.0M) |
Revelation Biosciences Institutional Holders
Institutional Holdings refers to the ownership stake in Revelation Biosciences that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Revelation Biosciences' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Revelation Biosciences' value.| Shares | Tower Research Capital Llc | 2025-03-31 | 2 K | Sbi Securities Co Ltd | 2025-06-30 | 1.4 K | Royal Bank Of Canada | 2025-03-31 | 1.4 K | Ubs Group Ag | 2025-03-31 | 349 | Bank Of America Corp | 2025-03-31 | 18.0 | Morgan Stanley - Brokerage Accounts | 2025-03-31 | 0.0 | Ifp Advisors, Llc | 2025-06-30 | 0.0 | Xtx Topco Ltd | 2025-03-31 | 0.0 | Two Sigma Securities, Llc | 2025-03-31 | 0.0 |
Revelation Fundamentals
| Return On Equity | -1.19 | ||||
| Return On Asset | -0.53 | ||||
| Current Valuation | (9.45 M) | ||||
| Shares Outstanding | 5.92 M | ||||
| Shares Owned By Insiders | 25.35 % | ||||
| Shares Owned By Institutions | 18.60 % | ||||
| Number Of Shares Shorted | 36.69 K | ||||
| Price To Earning | 8.69 X | ||||
| Price To Book | 0.30 X | ||||
| Price To Sales | 2.88 X | ||||
| Gross Profit | 90.91 M | ||||
| EBITDA | (7.95 M) | ||||
| Net Income | (15.04 M) | ||||
| Cash And Equivalents | 3.48 M | ||||
| Cash Per Share | 0.15 X | ||||
| Total Debt | 1.91 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 0.68 X | ||||
| Book Value Per Share | 3.07 X | ||||
| Cash Flow From Operations | (18.32 M) | ||||
| Short Ratio | 0.34 X | ||||
| Earnings Per Share | 81.25 X | ||||
| Target Price | 21.25 | ||||
| Beta | -0.13 | ||||
| Market Capitalization | 3.26 M | ||||
| Total Asset | 6.62 M | ||||
| Retained Earnings | (40.51 M) | ||||
| Working Capital | 4.65 M | ||||
| Net Asset | 6.62 M |
About Revelation Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Revelation Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Revelation Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Revelation Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| HITI | High Tide | |
| HITI | High Tide | |
| BAC | Bank of America |
Check out Revelation Biosciences Piotroski F Score and Revelation Biosciences Altman Z Score analysis. For information on how to trade Revelation Stock refer to our How to Trade Revelation Stock guide.You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Revelation Biosciences. If investors know Revelation will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Revelation Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Revelation Biosciences is measured differently than its book value, which is the value of Revelation that is recorded on the company's balance sheet. Investors also form their own opinion of Revelation Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Revelation Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Revelation Biosciences' market value can be influenced by many factors that don't directly affect Revelation Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Revelation Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Revelation Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Revelation Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.